Evolution of patient demographics, baseline clinical characteristics and outcomes in Phase 3 trials of biologics (TNFi, IL12/23i, IL17i, IL23i), PDE4i and TYK2i for psoriasis

Evolution of patient demographics, baseline clinical characteristics and outcomes in Phase 3 trials of biologics (TNFi, IL12/23i, IL17i, IL23i), PDE4i and TYK2i for psoriasis

Abstract Background Psoriasis, a common chronic inflammatory skin disease with major impact on quality of life, is associated with several comorbidities. A better understanding of the pathogenesis of psoriasis has led to the development and approval of new therapeutic strategies such as biologics of...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Sara Peeters, Kurt De Vlam, Hugo Boonen, Canan Güvenç, Tom Hillary
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: Wiley 2024-06-01
Sarja:JEADV Clinical Practice
Aiheet:
biologics
disease activity
disease characteristics
patient population characteristics
psoriasis
systemic therapy
Linkit:https://doi.org/10.1002/jvc2.355

Internet

https://doi.org/10.1002/jvc2.355

Samankaltaisia teoksia